Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival

Article ID	Journal	Published Year	Pages	File Type
5596833	The Annals of Thoracic Surgery	2017	6 Pages	PDF

Abstract

Operative mortality rate is high in patients receiving MB for the treatment of vasoplegia after cardiopulmonary bypass. Early administration of MB improves survival and reduces the risk-adjusted rate of major adverse events in these patients.

Keywords

SVR CPB STS ACE FDA Angiotensin-converting enzyme cardiopulmonary bypass MAE Society of Thoracic Surgeons Food and Drug Administration cardiac index major adverse event Methylene blue Systemic vascular resistance Nitric oxide

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Preview

Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival

Authors

J. Hunter MD, Lily E. MD, MPH, Robert B. MD, Eric J. MD, Leora MD, John A. MD, Gorav MD, Irving L. MD, Ravi K. MD,